Investigators assessed nitazoxanide (NTZ) in two uveal melanoma cell lines, Mel270 and Mel290. Short, clear cellular changes were observed after NTZ exposure. The study team reported that NTZ functions as a mitochondrial uncoupler in these UM cells, lowering mitochondrial membrane potential and decreasing the cellular oxygen consumption rate. Those bioenergetic shifts indicate impaired mitochondrial oxidative phosphorylation as a proximal effect of NTZ treatment. The authors concluded that this mitochondrial targeting exposes a druggable metabolic vulnerability in UM, based on the measured changes in membrane potential and respiration in vitro.
NTZ reduced cell growth across the tested UM cultures. In separate assays investigators observed reduced viability and impaired colony development after drug exposure. Short-term and longer-term readouts both showed diminished proliferative capacity. Flow cytometry data, as summarized in the abstract, showed cell‑cycle arrest with accumulation in G0–G1 phase after NTZ treatment. Cell motility assays indicated reduced migration in treated UM cells, suggesting an antimetastatic phenotype at the cellular level. The combined in vitro phenotypes—lower viability, fewer colonies, cell‑cycle blockade and less migration—formed a consistent pattern of growth and spread inhibition in cell culture.
Acute NTZ exposure triggered measurable shifts in canonical metabolic signaling. The study team observed increased phosphorylation of adenosine monophosphate‑activated protein kinase (AMPK), a sensor of cellular energy stress. Concurrently, authors reported downregulation of mTOR signaling and suppression of the acetyl‑CoA carboxylase (ACC) pathway. These signaling changes align with the reported mitochondrial uncoupling and lower oxidative phosphorylation; lower ATP production would be expected to engage AMPK and reduce anabolic mTOR/ACC activity. The abstract presents these molecular effects as mechanistic correlates linking NTZ‑induced bioenergetic impairment to reduced proliferation and migration in UM cells.
The investigators translated their in vitro observations into an in vivo metastasis model. Human UM cells were delivered intrasplenically into male non‑obese diabetic‑severe combined immunodeficient‑γ (NOD‑SCID‑γ) mice to generate hepatic metastases. Oral administration of NTZ to these animals reduced hepatic metastatic burden and tumor incidence relative to untreated controls, according to the abstract. These findings connect NTZ’s mitochondrial activity and signaling effects in vitro with a reduction in liver colonization by UM cells in an immunodeficient xenograft system. The data therefore support a role for mitochondrial oxidative phosphorylation in sustaining UM liver metastasis in this preclinical context.
The source material describes cell line experiments and a mouse xenograft model; it does not report human clinical data. The abstract did not provide specific NTZ dosing regimens, duration of treatment, pharmacokinetic measurements, or formal toxicity/safety data for the animal experiments. Investigators did not report patient-level outcomes or clinical trial results in this article. The reliance on two UM cell lines and an immunodeficient mouse model limits direct inference about efficacy in immunocompetent hosts or in patients with heterogeneous disease. The study team positioned mitochondrial oxidative phosphorylation as a therapeutic target in UM, but the abstract stopped short of outlining steps toward clinical translation, such as dose optimization, combination strategies, or biomarker development. These items remain unreported in the source and represent clear gaps for subsequent work.
The article provides preclinical evidence that NTZ alters mitochondrial function, shifts energy‑sensing pathways (AMPK, mTOR, ACC), reduces tumor cell proliferation and migration in vitro, and lowers hepatic metastasis incidence in an intrasplenic xenograft. The findings are limited to the described preclinical systems; the source did not document human dosing, safety, or clinical efficacy data. Next steps implied by these data—rigorous toxicology, pharmacokinetics, dose finding, and studies in immunocompetent or patient‑derived models—were not detailed in the abstract.